Last reviewed · How we verify
NCT06805617: I-MAC
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Phase 2 trial testing Ivonescimab in Salivary Gland Cancer in 35 participants. Currently enrolling.
1 July 2026
Quick facts
| Lead sponsor | Glenn J. Hanna |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 26 February 2025 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 July 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Ivonescimab — full drug profile →
Conditions studied
- Salivary Gland Cancer — all drugs for Salivary Gland Cancer →
- Advanced Salivary Gland Carcinoma — all drugs for Advanced Salivary Gland Carcinoma →
- Metastatic Salivary Gland Cancer — all drugs for Metastatic Salivary Gland Cancer →
- Adenoid Cystic Carcinoma — all drugs for Adenoid Cystic Carcinoma →
Sponsor
Glenn J. Hanna — full company profile →
Who can join
18 and older, any sex, with Salivary Gland Cancer or Advanced Salivary Gland Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06805617
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ivonescimab
Trials testing the same drug.
- NCT07405190 — Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226544 — Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer · Phase 2 · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
Other recruiting trials for Salivary Gland Cancer
Currently open trials in the same condition.
- NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
- NCT06695845 — A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors · Phase 2 · recruiting
- NCT05553782 — Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers · EARLY_PHASE1 · recruiting
- NCT05074940 — Amivantamab in Adenoid Cystic Carcinoma · Phase 2 · active not recruiting
- NCT05483374 — The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers · recruiting
Other Glenn J. Hanna trials
Trials by the same sponsor.
- NCT06940180 — Toripalimab With Chemotherapy for Sinus Cancer · Phase 2 · recruiting
- NCT06623110 — Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease · Phase 2 · recruiting
- NCT06239220 — PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC · Phase 2 · recruiting
- NCT05774899 — CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC · Phase 1, PHASE2 · recruiting
- NCT05057247 — Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06805617 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Glenn J. Hanna
- Last refreshed: 29 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06805617.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing